Trial Profile
Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin,versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus who have Undergone Percutaneous Coronary Intervention: Open-label Randomized Parallel-group Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms STILL-GLORY trial
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 04 Apr 2017 New trial record